Tofogliflozin, a selective inhibitor of SGLT2, has been reported to significantly reduce the cardio‐ankle vascular index in patients with T2DM after 6 months of starting treatment.45 The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.